The management of locally advanced prostate cancer.

abstract：BACKGROUND:The lack of sensitive and specific biomarkers for prostate cancer (PCa) has led to over-diagnosis and overtreatment with uncertain benefit. Therefore, biomarkers for early diagnosis that can distinguish aggressive from indolent tumors and that can detect metastatic or recurrent disease are needed. Long nonco...

journal_title：Prostate cancer and prostatic diseases

authors： Mouraviev V,Lee B,Patel V,Albala D,Johansen TE,Partin A,Ross A,Perera RJ

更新日期：2016-03-01 00:00:00

abstract：BACKGROUND:Certain patients presenting with either low or very-low-risk prostate cancer (PCa) can represent a therapeutic dilemma for physicians. The oncologic outcomes of active surveillance (AS) for men with very-low-risk PCa are overall excellent. However, there are concerns about AS related to the potential for upg...

journal_title：Prostate cancer and prostatic diseases

authors： Gökce MI,Sundi D,Schaeffer E,Pettaway C

更新日期：2017-06-01 00:00:00

abstract：BACKGROUND:To assess the added value of biopsy factors, like maximum cancer length in a core (MCL), cumulative cancer length (CCL), cumulative length of positive cores (CLPC), percentage of cancer involvement in positive cores (CIPC) and the Prostate Cancer Research International: Active Surveillance (PRIAS) criteria i...

journal_title：Prostate cancer and prostatic diseases

authors： Russo GI,Castelli T,Favilla V,Reale G,Urzì D,Privitera S,Fragalà E,Cimino S,Morgia G

更新日期：2015-12-01 00:00:00

abstract：BACKGROUND:To evaluate the safety and clinical feasibility of focal irreversible electroporation (IRE) of the prostate. METHODS:We assessed the toxicity profile and functional outcomes of consecutive patients undergoing focal IRE for localised prostate cancer in two centres. Eligibility was assessed by multi-parametri...

journal_title：Prostate cancer and prostatic diseases

authors： Valerio M,Stricker PD,Ahmed HU,Dickinson L,Ponsky L,Shnier R,Allen C,Emberton M

更新日期：2014-12-01 00:00:00

abstract：BACKGROUND:Tumour 18F-FDG-uptake is of prognostic value in high-risk and metastatic prostate cancer (PCa). The aim of this study is to investigate the underlying glucose metabolism mechanisms of 18F-FDG-uptake on PET/CT imaging in PCa. METHODS:Retrospective analysis was conducted for 94 patients diagnosed with a Gleas...

journal_title：Prostate cancer and prostatic diseases

authors： Meziou S,Ringuette Goulet C,Hovington H,Lefebvre V,Lavallée É,Bergeron M,Brisson H,Champagne A,Neveu B,Lacombe D,Beauregard JM,Buteau FA,Riopel J,Pouliot F

更新日期：2020-09-01 00:00:00

abstract：BACKGROUND:Oral antiandrogen therapies are predominantly used in older men, but real-life studies evaluating the impact of age on pharmacokinetic exposure are lacking. This study aims to evaluate the impact of age on the pharmacokinetic profiles of abiraterone acetate and enzalutamide in clinical practice. PATIENTS AN...

journal_title：Prostate cancer and prostatic diseases

authors： Crombag MBS,van Nuland M,Bergman AM,Rosing H,Schellens JHM,Huitema ADR,Beijnen JH

更新日期：2019-03-01 00:00:00

abstract：OBJECTIVE:To determine the prognostic value of serum chromogranin-A (CGA) in a two-cohort study of men with metastatic castrate resistant prostate cancer (mCRPC) and to compare with circulating tumor cells (CTCs)-based prognosis. PATIENTS AND METHODS:A two-cohort-based evaluation for serum CGA for prognostication in C...

journal_title：Prostate cancer and prostatic diseases

authors： Giridhar KV,Sanhueza C,Hillman DW,Alkhateeb H,Carlson R,Tan W,Costello BA,Quevedo F,Pagliaro L,Kohli M

更新日期：2018-09-01 00:00:00

abstract：BACKGROUND:Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is a common problem with unclear etiology. Some diet and lifestyle factors were thought to correlate with CP/CPPS, but studies comprehensively investigate this correlation are rarely available. The current study was conducted to determine the potenti...

journal_title：Prostate cancer and prostatic diseases

authors： Chen X,Hu C,Peng Y,Lu J,Yang NQ,Chen L,Zhang GQ,Tang LK,Dai JC

更新日期：2016-03-01 00:00:00

abstract：BACKGROUND:Overexpression of the ERG protein is highly prevalent in prostate cancer (PCa) and commonly results from gene fusions involving the ERG gene. Recently, N-terminal epitope-targeted mouse and a C-terminal epitope-targeted rabbit monoclonal anti-ERG antibody (ERG-MAbs) have been introduced for the detection of ...

journal_title：Prostate cancer and prostatic diseases

authors： Braun M,Goltz D,Shaikhibrahim Z,Vogel W,Böhm D,Scheble V,Sotlar K,Fend F,Tan SH,Dobi A,Kristiansen G,Wernert N,Perner S

更新日期：2012-06-01 00:00:00

abstract：:Some patients with a histopathological diagnosis of prostate cancer have a tumour that behaves benignly during long-term follow-up. The proportion of patients with such a tumour is unknown, as is the fraction who die of prostate cancer between 10 and 20 y of follow-up. All men aged 45-84 y obtaining a diagnosis of pro...

journal_title：Prostate cancer and prostatic diseases

authors： Adolfsson J,Oksanen H,Salo JO,Steineck G

更新日期：2000-07-01 00:00:00

abstract：BACKGROUND:In men with high Gleason PC and rapid PSA progression after surgery, failure rates remain unacceptably high despite salvage radiation. We explored a novel multimodality approach of docetaxel with anti-angiogenic therapy before salvage radiotherapy (RT). METHODS:This was a phase 2 single-arm prospective open...

journal_title：Prostate cancer and prostatic diseases

authors： Armstrong AJ,Halabi S,Healy P,Lee WR,Koontz BF,Moul JW,Mundy K,Creel P,Wood S,Davis K,Carducci MA,Stein M,Hobbs C,Reimer B,Nguyen M,Anand M,Bratt L,Kim S,Tran PT,George DJ,Department of Defense Prostate Cancer Cli

更新日期：2016-03-01 00:00:00

abstract：:The molecular mechanisms for hormone-resistant prostate cancer progression still remain elusive, mainly due to the limited availability of corresponding tissue. As transurethral resection (TUR) is a common palliative therapy for patients with hormone refractory prostate cancer (HRPC) who have subvesical obstruction, w...

journal_title：Prostate cancer and prostatic diseases

authors： Stoss O,Werther M,Zielinski D,Middel P,Jost N,Rüschoff J,Henkel T,Albers P

更新日期：2008-01-01 00:00:00

abstract：:As high grade PIN is commonly associated with concomitant cancer, current literature recommends re-biopsy of patients with high grade PIN. This paper describes the prevalence of high grade prostatic intra-epithelial neoplasia (PIN) from three independent clinical settings, reported by a single pathologist (MCP). High ...

journal_title：Prostate cancer and prostatic diseases

authors： Feneley MR,Green JS,Young MP,Bose P,Kirby RS,Peeling WB,Parkinson MC

更新日期：1997-12-01 00:00:00

abstract：:In light of the growing interest in the concept of 'uroselectivity' and in the increased worldwide use of alpha-blockers for benign prostatic hyperplasia (BPH), this review evaluates the relative benefits of various alpha-blocking agents in the treatment of BPH. The pharmacological and physiological selectivity as wel...

journal_title：Prostate cancer and prostatic diseases

authors： Lowe F

更新日期：1999-05-01 00:00:00

abstract：BACKGROUND:While direct-to-consumer (DTC) medical advertising can provide useful information, it also risks oversimplification and being misleading. For an abbreviated prostate cancer treatment regimen called "ultrahypofractionation" (UHF), advertising has been used for CyberKnife (CK), a common delivery system for ste...

journal_title：Prostate cancer and prostatic diseases

authors： Caputo JM,Lee HJ,Chiles B,Hyams ES

更新日期：2020-12-01 00:00:00

abstract：:In addition to androgen, autonomic nerves may be involved in prostatic function. As patients with spinal cord injury (SCI) have impaired innervation of the prostate, the prostate volume and prostate-specific antigen (PSA) level in patients with SCI may be different from those of healthy men. Experiments in rats with S...

journal_title：Prostate cancer and prostatic diseases

authors： Shim HB,Jung TY,Lee JK,Ku JH

更新日期：2006-01-01 00:00:00

abstract：BACKGROUND:Several treatment options for clinically localized prostate cancer currently exist under the established guidelines. We aim to assess nationally representative trends in treatment over time and determine potential geographic variation using two large national claims registries. METHODS:Men with prostate can...

journal_title：Prostate cancer and prostatic diseases

authors： Cary KC,Punnen S,Odisho AY,Litwin MS,Saigal CS,Cooperberg MR,NIDDK Urologic Diseases in America Project.

更新日期：2015-06-01 00:00:00

abstract：BACKGROUD:The European Organization for Research and Treatment of Cancer (EORTC) trial 22,911 reported 74% 5-year biochemical disease-free survival (bDFS) in patients with prostate carcinoma treated with radical prostatectomy (RP) followed by postoperative radiotherapy (RT). This study aimed to improve these outcomes b...

journal_title：Prostate cancer and prostatic diseases

authors： Mantini G,Siepe G,Alitto AR,Buwenge M,Nguyen NP,Farioli A,Schiavina R,Catucci F,Deodato F,Fionda B,Frascino V,Macchia G,Ntreta M,Padula GDA,Arcelli A,Cammelli S,Rambaldi GZ,Cilla S,Valentini V,Morganti AG

更新日期：2018-11-01 00:00:00

abstract：BACKGROUND:Prostate cancer (PCa) is characterized as the most frequent type of cancer in males. Recent research has suggested patients who have diabetes mellitus taking metformin (MF) have a lower risk of PCa. MF has antineoplastic effects such as adenosine monophosphate-activated protein kinase (AMPK)-dependent and in...

journal_title：Prostate cancer and prostatic diseases

authors： Zaidi S,Gandhi J,Joshi G,Smith NL,Khan SA

更新日期：2019-09-01 00:00:00

abstract：:Worldwide disparities exist between geographic regions with regard to prostate cancer incidence and mortality. Countries in East Asia have lower rates of prostate cancer compared with Western countries such as Canada and the US. Some suggest that dietary differences between the two geographic regions, particularly the...

journal_title：Prostate cancer and prostatic diseases

authors： Goetzl MA,Van Veldhuizen PJ,Thrasher JB

更新日期：2007-01-01 00:00:00

abstract：OBJECTIVE:To determine whether the duration of the off-treatment interval in patients being treated with intermittent androgen deprivation therapy can be predicted by the length of the CAG trinucleotide repeat polymorphism in the androgen receptor. METHODS:This is a companion study to a prospective randomized trial, N...

journal_title：Prostate cancer and prostatic diseases

authors： Klotz L,Correia A,Zhang W

更新日期：2005-01-01 00:00:00

abstract：:The aim of the present study was to investigate the differential expression of erythropoietin receptor (EPOR) in prostate carcinoma (PCa), high-grade prostatic intraepithelial neoplasia (PIN), prostatic hyperplasia (BPH) lesions and normal prostatic tissues by immunohistochemistry; and to test the hypothesis that upre...

journal_title：Prostate cancer and prostatic diseases

authors： Zhou T,Xu C,He M,Sun Y

更新日期：2008-01-01 00:00:00

abstract：BACKGROUND:Agent Orange (AO) was previously identified as a significant risk factor for biochemical recurrence (BCR) after radical prostatectomy (RP) in prostate cancer patients. In this study, we determined the levels of dioxin biological toxicity using toxic equivalency (TEQ) values and examined the impact of dioxin-...

journal_title：Prostate cancer and prostatic diseases

authors： Li Q,Lan L,Klaassen Z,Shah SR,Moses KA,Terris MK

更新日期：2013-12-01 00:00:00

abstract：:The aim of the present study was to evaluate how serum testosterone level (T) can affect urinary continence and erectile function in patients undergoing radical prostatectomy (RP). We included 257 patients with clinically localized prostate cancer, those who had filled out preoperative quality of life questionnaires (...

journal_title：Prostate cancer and prostatic diseases

authors： Gacci M,Corona G,Apolone G,Lanciotti M,Tosi N,Giancane S,Masieri L,Serni S,Maggi M,Carini M

更新日期：2010-06-01 00:00:00

abstract：:Randomized data from SWOG 8794 and EORTC 22911 confirm the benefit of post-operative radiation therapy (RT) for selected patients with pT3 prostate cancer (CaP) after radical prostatectomy (RP). However, data regarding the potential benefit of RT for patients post-RP with positive lymph node (+LN) involvement are limi...

journal_title：Prostate cancer and prostatic diseases

authors： Johnstone PA,Assikis V,Goodman M,Ward KC,Riffenburgh RH,Master V

更新日期：2007-01-01 00:00:00

abstract：BACKGROUND:Tumor contact length (TCL) is defined as the extent of contact between prostate cancer and the prostatic capsule, and its predictive value for microscopic extraprostatic extension (EPE) has been reported. However, the impact of the zonal origin (anterior or posterior tumor) of the tumor on the diagnosis of E...

journal_title：Prostate cancer and prostatic diseases

authors： Matsumoto K,Akita H,Narita K,Hashiguchi A,Takamatsu K,Takeda T,Kosaka T,Mizuno R,Kikuchi E,Oya M,Jinzaki M

更新日期：2019-12-01 00:00:00

abstract：:Prostate cancer appears to result from complex interactions among genetic, endocrine and environmental factors. Identification of risk factors for development and progression of prostate cancer is needed. This will allow researchers to design strategies to reduce the morbidity and mortality from this cancer and to ide...

journal_title：Prostate cancer and prostatic diseases

authors： Neuhausen SL

更新日期：2000-12-01 00:00:00

abstract：BACKGROUND:Berbamine (BBM) has been reported with antitumor activities. BBM inhibited the growth of prostate cancer (PCa) cells and caused vacuolization of mitochondria in preliminary study. We hypothesized BBM could enhance apoptosis of PCa cells through mitochondrial pathway. METHODS:Growth of PC-3 and LNCaP cells t...

journal_title：Prostate cancer and prostatic diseases

authors： Zhao Y,Lv JJ,Chen J,Jin XB,Wang MW,Su ZH,Wang LY,Zhang HY

更新日期：2016-12-01 00:00:00

abstract：:The objective of this work is to describe the profile of prevalent and incident populations suffering from lower urinary tract symptoms (LUTS) suggestive of benign prostatic obstruction (BPO) and to analyse the management of care by 620 general practitioners (GPs) in France in 1997 and 1998. Patient records were extra...

journal_title：Prostate cancer and prostatic diseases

authors： Vallancien G,Pariente P

更新日期：2001-01-01 00:00:00

abstract：BACKGROUND:The combination of abiraterone acetate and prednisone (AA/P) is used to treat metastatic prostate cancer, but molecular predictors of treatment response are not well elucidated. We evaluated plasma circulating tumor DNA- (ctDNA-) based copy number alterations (CNAs) to determine treatment-related predictive ...

journal_title：Prostate cancer and prostatic diseases

authors： Du M,Tian Y,Tan W,Wang L,Wang L,Kilari D,Huang CC,Wang L,Kohli M

更新日期：2020-12-01 00:00:00